Letter to the Editor
MEDICATION-RELATED OSTEONECROSIS OF JAW
1 Department of Oral and Maxillofacial Pathology, Awadh Dental College and Hospital, Jamshedpur, India
2 Department of Oral and Maxillofacial Pathology, Awadh Dental College and Hospital, Jamshedpur
3 Department of Oral Pathology, KGF College Of Dental Sciences And Hospital, Karnataka, India
4 Department of Biomedicine and Prevention, the University of Rome Tor Vergata, Rome, Italy
5 Department of Orthodontics, Faculty of Dentistry, Trakya University, Edirne, Turkey
6 Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico “Gaetano Martino”, Messina, Italy
7 Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India
Correspondence to:
Department of Oral and maxillofacial pathology,
Awadh Dental College and Hospital,
NH-33, Danga, P.O. Bhilaipahar, Jamshedpur,
Jharkhand 831012, India
e-mail: abhishek.banerjee376@gmail.com
Annals of Stomatology 2024 May-August 4(2): 83-86
https://doi.org/10.69129/stomatol/2024v4iss2_1
Received: 28 June 2024 Accepted: 2 August 2024
Copyright © by LAB srl 2024 ISSN 2975-1276
Download PDF
Abstract
Medication-related osteonecrosis of the jaws (MRONJ) primarily occurs as a complication of bone antiresorptive treatment in specific bone treatment modalities. It was first identified in 2003 as a bisphosphonate (BP) treatment complication. Denosumab is a molecule with a particular mode of action. This molecule inhibits bone resorption by suppressing osteoclast function. BPs have a strong affinity for hydroxyapatite crystals and remain in bone for years. The pathogenesis of MRONJ is not fully explained and appears multifactorial.
Keywords: antiresorptive, bisphosphonates, denosumab, medication-related osteonecrosis of jaw